title: Acetylcholine-induced aortic relaxation studied in salbutamol treated rats.
abstract: It has been proposed that the acetylcholine (ACh)-induced relaxation of the rat aorta is entirely mediated by endothelium derived-nitric oxide (NO). However, some authors have reported that indomethacin pretreatment attenuates ACh-induced relaxation of rat aortic ring preparations. Moreover, it has also been suggested that cAMP accumulation may regulate either nitric oxide synthase (NOS) or cyclooxygenase (COX) expression in different tissues. Thus, in this in vitro study we have investigated the endothelial mechanisms involved in the ACh-induced relaxation of ring preparations of the rat thoracic aorta, as well as the influence chronic treatment with the selective beta(2)-agonist salbutamol had upon such mechanisms. Results of functional experiments show that N(G)-monomethyl-L-arginine (L-NMMA, 3 x 10(-4) M) considerably inhibited the ACh-induced relaxation of rat aortic ring preparations. However, indomethacin (10(-5) M) was also found to partially attenuate this ACh response, suggesting that although NO is the most important mediator of the ACh-induced relaxation of the rat aortic ring preparations, vasorelaxation may also involve prostanoids. Moreover, the results suggest that treatment with salbutamol failed to produce any change in the ACh-induced relaxation of rat aortic ring preparations.
authors.affiliation: Laboratory of Pharmacology, School of Medicine of Marília, SP, Brazil.
authors.forename: Ednir O
authors.initials: EO
authors.lastname: Vizioli
authors.forename: Marcelo D
authors.initials: MD
authors.lastname: Spadin
authors.forename: Fernando M A
authors.initials: FM
authors.lastname: Corrêa
authors.forename: Fernanda
authors.initials: F
authors.lastname: Viaro
authors.forename: Paulo R B
authors.initials: PR
authors.lastname: Evora
authors.forename: Agnaldo B
authors.initials: AB
authors.lastname: Chies
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology*; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000420:Albuterol / Q000494:pharmacology*; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects* / Q000502:physiology; D000242:Cyclic AMP / Q000032:analysis / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000737:chemistry / Q000502:physiology; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects / Q000502:physiology; D009131:Muscle, Smooth, Vascular / Q000737:chemistry / Q000502:physiology; D009569:Nitric Oxide / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000502:physiology; D011453:Prostaglandins / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D019323:omega-N-Methylarginine / Q000494:pharmacology
chemical_list: D000318:Adrenergic beta-Agonists; D011453:Prostaglandins; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D000242:Cyclic AMP; D019001:Nitric Oxide Synthase; D000109:Acetylcholine; D000420:Albuterol; D007213:Indomethacin